Dr Reddys Laboratories Shares Outstanding History (RDY)
Dr Reddys Laboratories reported 832.6M shares outstanding at the end of fiscal 2025.
View full Dr Reddys Laboratories company overviewDr Reddys Laboratories annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-03-31 | 832.6M | 1.9M | +0.22% |
| 2024 | 2024-03-31 | 830.8M | 996,770 | +0.12% |
| 2023 | 2023-03-31 | 829.8M | 664.1M | +400.70% |
| 2022 | 2022-03-31 | 165.7M | −50,102 | −0.03% |
| 2021 | 2021-03-31 | 165.8M | −71,840 | −0.04% |
| 2020 | 2020-03-31 | 165.8M | −62,935 | −0.04% |
| 2019 | 2019-03-31 | 165.9M | 169,194 | +0.10% |
| 2018 | 2018-03-31 | 165.7M | −4.9M | −2.85% |
| 2017 | 2017-03-31 | 170.6M | 226,479 | +0.13% |
| 2016 | 2016-03-31 | 170.4M | — | — |
Dr Reddys Laboratories quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-03-31 | 832.6M | 666.9M | +402.27% |
| Q4 2024 | 2024-03-31 | 830.8M | 664.9M | +400.93% |
| Q4 2023 | 2023-03-31 | 829.8M | 663.9M | +400.14% |
| Q4 2022 | 2022-03-31 | 165.7M | −15,683 | −0.01% |
| Q4 2021 | 2021-03-31 | 165.8M | −4.8M | −2.83% |
| Q4 2020 | 2020-03-31 | 165.8M | −4.5M | −2.66% |
| Q4 2019 | 2019-03-31 | 165.9M | — | — |
| Q4 2018 | 2018-03-31 | 165.7M | — | — |
| Q4 2017 | 2017-03-31 | 170.6M | — | — |
| Q4 2016 | 2016-03-31 | 170.4M | — | — |
Dr Reddys Laboratories shares outstanding trends
Over the last five reported fiscal years, Dr Reddys Laboratories's shares outstanding moved from 165.8M to 832.6M, a change of 666.8M. The latest reported quarter, Q4 2025, shows 832.6M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dr Reddys Laboratories filings at SEC.gov ↗